Hussman Strategic Advisors Inc. Invests $1.56 Million in InMode Ltd. $INMD

Hussman Strategic Advisors Inc. acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 105,000 shares of the healthcare company’s stock, valued at approximately $1,564,000. Hussman Strategic Advisors Inc. owned 0.17% of InMode at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in INMD. Blue Trust Inc. lifted its stake in InMode by 93.7% in the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock valued at $43,000 after buying an additional 1,384 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of InMode in the 3rd quarter worth about $52,000. Pilgrim Partners Asia Pte Ltd bought a new stake in InMode in the 3rd quarter valued at about $69,000. Farther Finance Advisors LLC lifted its position in InMode by 302.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 8,110 shares of the healthcare company’s stock valued at $117,000 after purchasing an additional 6,094 shares during the last quarter. Finally, Ritholtz Wealth Management acquired a new position in InMode during the 2nd quarter valued at about $151,000. 68.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on INMD shares. Canaccord Genuity Group set a $15.00 price target on shares of InMode and gave the company a “hold” rating in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a research report on Thursday, January 22nd. BTIG Research reaffirmed a “neutral” rating on shares of InMode in a research note on Monday. UBS Group reduced their price target on InMode from $16.25 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Friday, October 10th. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.60.

InMode Price Performance

INMD opened at $15.12 on Thursday. The business has a 50 day moving average price of $14.43 and a two-hundred day moving average price of $14.62. The company has a market capitalization of $955.74 million, a price-to-earnings ratio of 7.00 and a beta of 2.13. InMode Ltd. has a 1-year low of $13.14 and a 1-year high of $19.78.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.